Hologic (NASDAQ:HOLX) Downgraded to “Hold” Rating by Leerink Partnrs

Hologic (NASDAQ:HOLX) was downgraded by equities research analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports. Leerink Partnrs also issued estimates for Hologic’s Q3 2025 earnings at $1.10 EPS, FY2025 earnings at $4.27 EPS, Q1 2026 earnings at $1.14 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.17 EPS, FY2026 earnings at $4.60 EPS and FY2027 earnings at $4.88 EPS.

Other equities analysts also recently issued reports about the company. Royal Bank of Canada decreased their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday. UBS Group boosted their price objective on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Wolfe Research assumed coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. Raymond James reissued an “outperform” rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a report on Thursday. Finally, JPMorgan Chase & Co. increased their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Ten equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Stock Performance

Shares of HOLX opened at $65.45 on Thursday. The stock has a market capitalization of $14.77 billion, a PE ratio of 19.65, a price-to-earnings-growth ratio of 2.35 and a beta of 0.98. The business’s fifty day moving average price is $72.63 and its 200 day moving average price is $77.86. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic has a 12-month low of $64.87 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Equities research analysts forecast that Hologic will post 4.28 EPS for the current year.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.88% of the company’s stock.

Institutional Trading of Hologic

A number of hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC grew its holdings in Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares during the period. Nordea Investment Management AB grew its stake in shares of Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after purchasing an additional 544,889 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Hologic in the 4th quarter worth approximately $27,007,000. Swedbank AB lifted its stake in Hologic by 18.8% during the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after purchasing an additional 306,562 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Hologic by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after purchasing an additional 238,222 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.